Status:
TERMINATED
Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
COVID
Corona Virus Infection
Eligibility:
All Genders
18-80 years
Brief Summary
COVID-19 patients with a severely symptomatic progression with development of an Acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 need prolonged intensive care treatment involving pharmaco...
Detailed Description
COVID-19 patients with a severely symptomatic progression with development of an ARDS due to SARS-CoV-2 need prolonged intensive care treatment involving pharmacological immobilization, sedation and m...
Eligibility Criteria
Inclusion
- Informed consent as documented by a surrogate assessment by an independent physician
- Adult ICU Patients with ARDS due to SARS-CoV-2 requiring mechanical ventilation
Exclusion
- Age \<18 years and \> 80 years
- Pregnancy and breast feeding
- The presence of pre-existing:
- Known (at time of inclusion) Polyneuropathy,
- Known (at time of inclusion) Guillain-Barré syndrome,
- Known (at time of inclusion) Acute or chronic spinal cord lesion,
- Known (at time of inclusion) Myasthenia gravis, or
- Known (at time of inclusion) Myopathy
Key Trial Info
Start Date :
April 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 27 2023
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04397172
Start Date
April 9 2020
End Date
November 27 2023
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inselspital Bern
Bern, Switzerland, 3010